Related Experiment Video
Updated: Jun 24, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients
Rastee H Saeed1, Zirak Faqe Ahmed Abdulrahman1, Dara K Mohammad2,3
1Department of Biology, College of Education, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq.
Abstract:
MicroRNAs (miRNAs) are key regulators in Acute Myeloid Leukemia AML, affecting gene expression, including that of CD markers and impacting mutations within leukemic cells. Mutations in AML can alter miRNA profiles, which can affect the expression of CD markers and contribute to disease progression by influencing cellular processes such as differentiation, proliferation, and apoptosis. Here, we examined the interplay of cell surface protein expression (CD markers), DNA mutations, and microRNA expression in AML patients. We included 32 recently diagnosed AML patients, and CD marker expression was evaluated using flow cytometry and molecular techniques. This study aims to delve into this relationship within the context of AML, elucidating its potential implications for diagnosis, prognosis, and therapeutic interventions. Mutations were scrutinized in six patients using Whole-Exome Sequencing (WES), while quantitative PCR (qPCR) was employed to investigate the expression levels of nine microRNAs. Subsequently, a comprehensive interaction network was constructed using Cytoscape software, focusing on genes with significant mutations and their corresponding microRNAs. Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients. The molecular analysis results unveiled mutations in specific genes (FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS) targeted by nine microRNAs. Notably, eight microRNAs exhibited heightened expression levels. Network analysis highlighted interactions between the PTPN11 gene and six scrutinized microRNAs. Understanding the regulatory dynamics between gene mutations and microRNAs in AML patients is pivotal for unraveling the disease's molecular mechanisms and identifying potential therapeutic targets. Further exploration into the functional roles of microRNAs in gene regulation and AML pathogenesis is warranted to validate their potential as therapeutic targets, diagnostic markers, and advanced treatment strategies.
Insights
MicroRNAs regulate Acute Myeloid Leukemia (AML) by affecting gene mutations and CD marker expression. This study reveals key interactions between mutated genes and microRNAs in AML patients, offering potential therapeutic targets.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are crucial regulators in Acute Myeloid Leukemia (AML), influencing gene expression, CD marker profiles, and leukemic cell mutations.
- Altered miRNA profiles in AML can impact CD marker expression, disease progression, and cellular processes like differentiation, proliferation, and apoptosis.
Purpose of the Study:
- To investigate the intricate relationship between cell surface protein (CD marker) expression, DNA mutations, and miRNA expression in AML patients.
- To elucidate the potential diagnostic, prognostic, and therapeutic implications of these molecular interactions in AML.
Main Methods:
- Analysis of CD marker expression using flow cytometry and molecular techniques in 32 AML patients.
- Whole-Exome Sequencing (WES) for mutation analysis in six patients and quantitative PCR (qPCR) for nine miRNA expression levels.
- Construction of an interaction network using Cytoscape to map gene mutations and their corresponding microRNAs.
Main Results:
- Upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15, and CD117 observed in AML patients.
- Identified mutations in FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS genes targeted by specific miRNAs.
- Eight miRNAs showed elevated expression; network analysis revealed significant interactions between the PTPN11 gene and six miRNAs.
Conclusions:
- Understanding the interplay between gene mutations and miRNAs in AML is vital for deciphering disease mechanisms.
- These regulatory dynamics highlight potential therapeutic targets for AML diagnosis, prognosis, and treatment strategies.
- Further research into miRNA functions in AML pathogenesis is warranted to validate their clinical utility.
Related Concept Videos
MicroRNAs
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

